Silence Therapeutics (SLN) Accounts Payables (2018 - 2026)

Silence Therapeutics (SLN) posted Accounts Payables of $10.4 million for Q1 2026, down 22.38% sequentially from $13.4 million in Q4 2025, and down 44.89% YoY from $18.8 million in Q1 2025.

Silence Therapeutics (SLN) Accounts Payables (2018 - 2026) Analysis & Trends

Silence Therapeutics has reported Accounts Payables for 9 years, with the latest figure at $10.4 million in Q1 2026.

  • Quarterly Accounts Payables fell 44.89% year-over-year to $10.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $10.4 million (down 44.89% YoY) and the FY2025 annual result came in at $13.4 million, down 18.56% from the prior year.
  • Accounts Payables retreated to $10.4 million in Q1 2026 per SLN's latest filing, from $13.4 million in the prior quarter.
  • Over five years, Accounts Payables peaked at $18.8 million in Q1 2025 and troughed at $10.4 million in Q1 2026.
  • A 5-year average of $15.1 million and a median of $15.1 million in 2023 frame the typical range for Accounts Payables.
  • The sharpest annual moves came in 2024 and 2026: Accounts Payables advanced 6.31% in 2024, then slumped 44.89% in 2026.
  • Over 5 years, Accounts Payables stood at $14.8 million in 2022, then increased by 4.11% to $15.4 million in 2023, then advanced by 6.31% to $16.4 million in 2024, then declined by 18.56% to $13.4 million in 2025, then slipped by 22.38% to $10.4 million in 2026.
  • According to Business Quant data, Accounts Payables over the past three periods registered $10.4 million, $13.4 million, and $17.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Accounts Payables (Qtr)
1 Vertex Pharmaceuticals 128.13 Bn 120.28 Bn 2.84 Bn 429.50 Mn
2 Regeneron Pharmaceuticals 112.33 Bn 104.33 Bn 3.93 Bn 1.16 Bn
3 Argenx Se 53.24 Bn 48.05 Bn 1.41 Bn 1.52 Bn
4 Revolution Medicines 43.64 Bn 43.64 Bn - 88.42 Mn
5 BeOne Medicines 39.27 Bn 34.17 Bn 1.53 Bn 470.30 Mn
6 MindWalk Holdings 35.32 Bn 35.31 Bn 1.82 Bn 3.05 Mn
7 Royalty Pharma 33.72 Bn 35.84 Bn - 35.57 Mn
8 Alnylam Pharmaceuticals 30.58 Bn 27.27 Bn 992.69 Mn 108.02 Mn
9 Insmed 27.01 Bn 25.85 Bn 358.27 Mn 428.93 Mn
10 Silence Therapeutics 648.22 Mn 576.12 Mn - 12.61 Mn

Historic Data

Download Data
DateValue
Jun 30, 2026 12.61 Mn
Mar 31, 2026 10.37 Mn
Dec 31, 2025 13.36 Mn
Sep 30, 2025 16.99 Mn
Jun 30, 2025 14.31 Mn
Mar 31, 2025 18.81 Mn
Dec 31, 2024 16.40 Mn
Dec 31, 2023 15.43 Mn
Dec 31, 2022 14.82 Mn
Dec 31, 2021 14.54 Mn
Dec 31, 2020 10.82 Mn
Dec 31, 2019 8.86 Mn
Dec 31, 2018 4.93 Mn